Since the effective crizotinib treatment for EML4-ALK has been observed to decrease the levels of EML4-ALK transcripts in TEPs during the treatment of NSCLC patients, it becomes possible to monitor TEP RNA to comprehend the drug therapy in these individuals with NSCLC (Nilsson et al. 2015). Here, ALK is linked to non-small cell lung carcinoma.